Sign inJoin waitlistJoin the waitlist

Collin Blakely

Associate Professor · University of California (San Francisco) School of Medicine

Credentials: · · · · ·

History

University of California-San Francisco
2009–2011
Internal Medicine
University of Pennsylvania Health System
2007–2009
University
Perelman School of Medicine at the University of Pennsylvania
2003–2007
University of Pennsylvania

Research

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
The Lancet Oncology · 2020 · 1,363 citations
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Cell · 2020 · 568 citations
Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation
Molecular and Cellular Biology · 1998 · 500 citations

Trever Bivona
30 papers
CM
Caroline Mccoach
14 papers · 1 as a fellow
Jonathan Riess
12 papers
Julia Rotow
12 papers · 1 as a fellow
Matthew Gubens
12 papers
Victor Olivas
10 papers
RD
Robert Doebele
9 papers
DJ
David Jablons
7 papers
Turja Chakrabarti
5 papers · 3 as a fellow
Anatoly Urisman
4 papers
Dara Aisner
4 papers
Gavitt Woodard
4 papers · 2 as a fellow

Grants

Bay Area & Anderson Team Against Acquired Resistance - u54 Program (Baataar-Up)
National Cancer Institute · U54
Project lead · $778.8K · University of California, San Francisco
2017–2027

Clinical trials

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
Principal investigator · Terminated · Phase 1
Collin Blakely
2022–2024
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Principal investigator · Terminated · Phase 1
University of California, San Francisco
2020–2022
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Principal investigator · Completed · Phase 1
Collin Blakely
2019–2025
Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
Principal investigator · Active not recruiting · Phase 2
University of California, San Francisco
2018–2027